Biodesix, APAPP Partner to Launch First CME-Accredited Education Program for Lung Cancer Biomarkers

Biodesix Inc. (NASDAQ:BDSX) is one of the best penny stocks under $1 to buy now. On June 10, Biodesix announced a new partnership with the Association of Pulmonary Advanced Practice Providers/APAPP. The collaboration aims to deliver the nation’s first CME-accredited medical education program for Advanced Practice Providers/APPs, focusing on the clinical application of diagnostic biomarkers in lung nodule and lung cancer programs.

The partnership will introduce new educational resources for Lung Health providers, specifically on innovative lung nodule risk assessment testing, such as the Nodify Lung blood-based tests, and cancer treatment decision support testing, such as the IQLun blood-based tests.

Biodesix, APAPP Partner to Launch First CME-Accredited Education Program for Lung Cancer Biomarkers

A laboratory technician viewing a microscope slide containing a sample of a blood-based lung test.

According to the American Lung Association, lung cancer remains the deadliest of all cancers, claiming nearly as many American lives annually as breast, prostate, and colon cancers combined.

Biodesix Inc. (NASDAQ:BDSX) is a diagnostic solutions company that offers blood-based lung tests to assess the risk of lung cancer and identify the appropriate treatment pathway.

While we acknowledge the potential of BDSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BDSX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.